SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, nsomniyak, Bob Stocks, bUrRpPPP!, runncoach, kld2
Search This Board: 
Last Post: 5/27/2017 3:08:44 PM - Followers: 72 - Board type: Free - Posts Today: 7

NTRPD Security Details
Share Structure


Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017

COMPANY PRESENTATION

http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf

Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million

 

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

Trial details 
NTRP Security Details
 
 
 
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP
Current Price
Volume:
Bid Ask Day's Range
NTRP News: Quarterly Report (10-q) 05/12/2017 05:21:20 PM
NTRP News: Current Report Filing (8-k) 05/01/2017 06:31:28 AM
NTRP News: NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease 05/01/2017 06:30:00 AM
NTRP News: Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017 04/28/2017 07:30:00 AM
NTRP News: Notice of Effectiveness (effect) 04/24/2017 06:01:54 AM
PostSubject
#4967  Sticky Note Full 2a trial article. Some incredible and runncoach 05/15/17 05:57:37 PM
#4691  Sticky Note NEUROTROPE Announces Positive Top-Line Results From Phase 2 bUrRpPPP! 05/02/17 03:05:10 PM
#3579  Sticky Note OK folks. While we realize that an occasional IH Admin [Edward] 04/17/17 09:53:57 PM
#1870  Sticky Note NTRP has updated their Company presentation on their website: SF Wolf 03/14/17 08:33:06 AM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#5009   Don't know can't tell. Also doesn't matter. nsomniyak 05/27/17 03:08:44 PM
#5008   Who had already bought then? Tia runncoach 05/27/17 03:02:32 PM
#5007   All institutions are listed as "new" because this XenaLives 05/27/17 02:51:04 PM
#5006   One funny thing was that some were claiming runncoach 05/27/17 11:57:01 AM
#5004   As far as liquidity goes, the only danger nsomniyak 05/27/17 11:52:23 AM
#5003   All that matters is when the stock runs XenaLives 05/27/17 11:17:01 AM
#5002   "NTRP is a low volume stock" Whatsupp 05/26/17 05:25:54 PM
#5001   Plenty of ways for investors to make money runncoach 05/26/17 10:55:46 AM
#5000   Only the traders - not for investors... XenaLives 05/26/17 10:22:28 AM
#4999   And the same reason people made so much runncoach 05/26/17 10:16:26 AM
#4998   This stock is always illiquid - that's why XenaLives 05/26/17 10:07:52 AM
#4997   Yep, day before a holiday weekend trading and runncoach 05/26/17 09:57:10 AM
#4996   Be aware - NTRP is a low volume XenaLives 05/26/17 09:40:26 AM
#4995   I wouldn't expect much news this week leading runncoach 05/23/17 07:55:54 AM
#4994   Things are awfully quiet here. Marlseg 05/23/17 07:06:09 AM
#4993   I think besides getting more detail info from Whatsupp 05/18/17 05:51:33 PM
#4992   I'm not sure how it plays out near runncoach 05/18/17 05:40:46 PM
#4991   Looks like some before and some after with MaxTok 05/18/17 04:14:58 PM
#4990   Do you know when these institution investors bought Maple tree 05/18/17 03:39:17 PM
#4989   Thanks! All makes sense now. Thank you to MaxTok 05/18/17 01:20:43 PM
#4988   The shares listed are from before the Whatsupp 05/18/17 01:14:30 PM
#4987   The 13G filing would be as a percentage wiltonio 05/18/17 01:13:55 PM
#4986   HBC (and other institutions) will always report their nsomniyak 05/18/17 01:07:50 PM
#4985   Still some errors reported due to r/s. I've runncoach 05/18/17 12:50:23 PM
#4984   Have a question, would appreciate it, if anyone MaxTok 05/18/17 12:08:20 PM
#4983   Latest on institutional buyers moving in: https://fintel.io/sob/us/ntrp Institut MaxTok 05/18/17 11:52:08 AM
#4980   Do you know how many people on aricept runncoach 05/16/17 02:05:06 PM
#4979   You mean I'm usually right. I said that blu_1 05/16/17 01:56:48 PM
#4977   Yes and some of the same people telling runncoach 05/16/17 01:16:57 PM
#4976   So ridiculous to call this a P&D. The MaxTok 05/16/17 12:44:38 PM
#4975  Restored If you think this is a P&D stock, blu_1 05/16/17 11:53:32 AM
#4973   Coach - could you sticky your post, thanks Whatsupp 05/16/17 09:59:16 AM
#4972   That "pond scum" issue didn't seem to stop Pika_1 05/16/17 08:14:52 AM
#4971   Coach, Agreed, moreover If I was NTRP I MrGuru 05/16/17 08:12:42 AM
#4970   I think one of the issues is the runncoach 05/15/17 07:58:38 PM
#4969   This can explain why the 40 ug/M2 dosis MrGuru 05/15/17 07:33:53 PM
#4968   MaxTok: MrGuru 05/15/17 07:09:43 PM
#4967   Full 2a trial article. Some incredible and runncoach 05/15/17 05:57:37 PM
#4966   Any thoughts on advantages of Options? July 21st MaxTok 05/15/17 04:12:07 PM
#4964  Restored Yes maybe if saliva did not destroy it Bearly Bullish 05/15/17 10:51:16 AM
#4963   Coach, Maple tree 05/14/17 11:25:33 PM
#4962   Wrong. PSEN1 AD mutation, which Jenni had, InTheTrenches 05/14/17 06:19:58 PM
#4961   Her seizures have been discussed here over and runncoach 05/14/17 05:22:24 PM
#4960   Jenni died prematurely from a seizure induced pneumonia. blu_1 05/14/17 05:11:57 PM
#4959   It's amazing how much joy that "pond scum" runncoach 05/14/17 03:59:18 PM
#4958  Restored The thing is, it doesn't have to be runncoach 05/14/17 03:49:43 PM
#4957   Oh, I HIGHLY doubt the release of that blu_1 05/14/17 03:31:11 PM
#4956   Incredibly impressive? Seriously? blu_1 05/14/17 03:23:04 PM
#4955   This is the info on a high level Whatsupp 05/14/17 02:13:24 PM
#4954   I don't honestly know. Per the presentations runncoach 05/14/17 12:47:26 PM
PostSubject